Litigation Challenges Prioritization of Race or Ethnicity in Allocating COVID-19 Therapies

By FYH News Team

Published on March 29, 2022

[ad_1]

Recent guidance from the U.S. Food & Drug Administration (FDA) encouraged several states to adopt policies that prioritized race or ethnicity in the allocation of monoclonal antibody treatments and oral antivirals for the treatment of SARS-CoV-2.
The guidance proved to be highly controversial, prompting two states, Utah and Minnesota, to withdraw their…

Read Full Story

If the content contained herein violates any of your rights, including those of copyright, you are requested to immediately notify us using via the following email address operanews-external(at)opera.com

Top News

comments

Load app to read more comments

[ad_2]

Source link

Features

Download and distribute powerful vaccination QI resources for your community.

MCED tests use a simple blood draw to screen for many kinds of cancer at once.

FYHN is a bridge connecting health information providers to BIPOC communities in a trusted environment.

Discover an honest look at our Medicare system.

ARC was launched to create a network of community clinicians to diversify and bring clinical trials to communities of color and other communities that have been underrepresented.